Search for: "Roche Therapeutics, Inc."
Results 21 - 40
of 51
Sorted by Relevance
|
Sort by Date
23 Feb 2011, 10:18 pm
Hoffmann-La Roche Inc., 541 F.3d 1115, 1122 (Fed. [read post]
17 Mar 2011, 11:55 am
Hoffmann-La Roche Inc., 541 F.3d 1115, 1122 (Fed. [read post]
23 Feb 2011, 9:49 am
Hoffmann-La Roche Inc., 541 F.3d 1115, 1122 (Fed. [read post]
12 Feb 2009, 10:42 am
Hoffman-La Roche, Inc., 618 N.W.2d 827, 837 (Neb. 2000); Bish v. [read post]
12 Oct 2018, 1:24 pm
Apotex, Inc., 550 F.3d 1075, 1086 (Fed. [read post]
25 Nov 2009, 3:00 am
(Patents4Life) R&D: the biggest spenders – discussion of 2009 EU Industrial R&D Scoreboard (IPKat) New search tool by OHIM and participating offices (Class 46) EPO – Many more changes coming next year (IPKat) EU-South Korea Free Trade Agreement: For the first time in a bilateral agreement between EU and a third country, the EU provides for the protection of European geographical indications (Class 46) Three more PGI regulations in force: Limone Interdonato Messina, Proscuitto di… [read post]
13 May 2009, 8:00 pm
Amgen Inc. v. [read post]
15 Nov 2011, 3:58 pm
They also chose a particularly challenging target for the first therapeutic application. [read post]
23 Mar 2011, 1:30 pm
The drug is jointly developed by Genentech Inc., a member of the Roche group, under an agreement with Novartis Pharma AG. [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]
18 Feb 2010, 10:34 am
Most notably there’s Mylan Laboratories, Inc. v. [read post]
9 May 2008, 10:30 pm
: (Spicy IP), India: Merck vs Roche: towards differential pricing: (Spicy IP), India/Philippines: Access to drugs: The India/Philippines solution? [read post]
18 Jul 2008, 8:34 am
: (GenericsWeb), Eularis analyses most effective generics defence strategies with new pharmaceutical industry report: (GenericsWeb), WIPO symposium to discuss life sciences multilateral environmental agreements: (Daily Dose of IP), Daiichi Sankyo and Ranbaxy confirm deal is binding and final, allay market rumour and speculation: (SmartBrief), Daiichi Ranbaxy takeover and the implications for the future of IP: (Spicy IP), Europe: Cancer Research Therapeutics’ RNAi patent revoked by… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces… [read post]
8 Apr 2010, 9:48 am
Roche Laboratories, Inc., 243 F. [read post]
15 Feb 2008, 9:00 am
: (Spicy IP),USD 20 billion going off-patent: (Patent Circle),Canadian Prices Review Board asserts jurisdiction over products sold in US, but imported into Canada under Special Access Program: (Gowlings),Canadian Court of Appeal affirms decision allowing patent-owner to be joined to proceedings: Cobalt v Pfizer and Pharmascience v Pfizer: (Gowlings),PharmaStem appeals stem cell patent: asks for greater deference to patent examiners: PharmaStem … [read post]
24 Apr 2020, 6:58 am
Both the Federal Circuit and the predecessor Court of Claims have deemed reasonable royalty awards to be “the preferred manner” of compensation under section 1498; in Tektronix Inc. v. [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram)… [read post]
19 Mar 2022, 2:09 pm
Risk assessments would seemingly be about assessing risks, but they are not. [read post]
5 Jul 2008, 11:05 am
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
